This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Bioethics Council will maintain regular dialogue with Bayer leadership on the implementation and long-term development of Bayer’s Bioethics Policy. The Bioethics Council will maintain regular dialogue with Bayer leadership on the implementation and long-term development of Bayer’s Bioethics Policy. “I
Over the years, Advarra has reviewed a wide range of clinical research studies and worked every day alongside leading pharmaceutical manufacturers, medical researchers, and healthcare institutions. Without clinical research, these medical breakthroughs would remain out of reach for patients.
American Society of Gene and Cell Therapy Annual Meeting Location: Baltimore, Maryland Dates: May 7 – 11, 2024 The main aim of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting is to provide a platform for sharing research, advancements, and ideas in the field of gene and cell therapy.
You can do a challenge trial with deadly diseases, but you need a “rescue therapy.” People are hesitant to do this because it's not a particularly flashy disease to research, nor is this population the focus of major pharmaceutical companies. So you have to do a field study. So that's a drawback.
Authors of “ An ethical exploration of barriers to research on controlled drugs ” in the American Journal of Bioethics have been quoted stating, “the classification of drugs as Schedule I amounts to an unsurmountable barrier to research.” About BetterLife Pharma Inc. BetterLife Pharma Inc.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content